Literature DB >> 15591025

DNA methylation affects cell proliferation, cortisol secretion and steroidogenic gene expression in human adrenocortical NCI-H295R cells.

J Liu1, X-D Li, A Vaheri, R Voutilainen.   

Abstract

Aberrant DNA methylation may be involved in human adrenocortical tumorigenesis, which is often accompanied by abnormal hormone production. In this study, we aimed to clarify the effects of DNA methylation on steroidogenesis using the human adrenocortical NCI-H295R cell line as a model. Treatment with the DNA methylation inhibitor 5-aza-2'-deoxycytidine (Azad; 10 microM for 7 days) decreased the proliferation rate to approximately 20% and the cell number to 60% of the control, with a simultaneous increase in the expression of the cyclin-dependent kinase inhibitor p57(KIP2) gene. In addition, Azad treatment increased cortisol secretion dose and time dependently, whereas dehydroepiandrosterone sulfate secretion was not affected. Azad treatment decreased basal and (Bu)2cAMP-induced expression of low- and high-density lipoprotein receptor, steroidogenic acute regulatory protein (StAR), cholesterol side-chain cleavage enzyme, steroid 17alpha-hydroxylase/17,20-lyase and steroid 21-hydroxylase mRNA, as well as the StAR protein level. In contrast, Azad treatment increased the basal expression of steroid 11beta-hydroxylase and 3beta-hydroxysteroid dehydrogenase/Delta5-Delta4-isomerase genes, although it inhibited the (Bu)2cAMP-induced expression of these two genes. The expression of steroidogenic factor-1 (SF-1) and DAX-1 (dosage-sensitive sex reversal-adrenal hypoplasia congenita critical region on the X-chromosome 1) genes (both harboring putative CpG islands in their promoters) and the methylation degree of the HpaII recognition site(s) in the SF-1 gene promoter region were reduced by Azad treatment. The immunostaining pattern of the methyl-CpG-binding protein MeCP2 was also modified by Azad treatment. These results suggest that DNA methylation may be implicated in the regulation of cell proliferation and steroidogenesis in human adrenocortical cells.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15591025     DOI: 10.1677/jme.1.01560

Source DB:  PubMed          Journal:  J Mol Endocrinol        ISSN: 0952-5041            Impact factor:   5.098


  11 in total

1.  Antineoplastic effects of decitabine, an inhibitor of DNA promoter methylation, in adrenocortical carcinoma cells.

Authors:  Insoo Suh; Julie Weng; Gustavo Fernandez-Ranvier; Wen T Shen; Quan-Yang Duh; Orlo H Clark; Electron Kebebew
Journal:  Arch Surg       Date:  2010-03

2.  Cell-Specific Polymorphism and Hormonal Regulation of DNA Methylation in Scavenger Receptor Class B, Type I.

Authors:  Zhigang Hu; Jiaxin Li; Zhihui Kuang; Meina Wang; Salman Azhar; Zhigang Guo
Journal:  DNA Cell Biol       Date:  2016-03-16       Impact factor: 3.311

3.  Targeted Assessment of G0S2 Methylation Identifies a Rapidly Recurrent, Routinely Fatal Molecular Subtype of Adrenocortical Carcinoma.

Authors:  Dipika R Mohan; Antonio Marcondes Lerario; Tobias Else; Bhramar Mukherjee; Madson Q Almeida; Michelle Vinco; Juilee Rege; Beatriz M P Mariani; Maria Claudia N Zerbini; Berenice B Mendonca; Ana Claudia Latronico; Suely K N Marie; William E Rainey; Thomas J Giordano; Maria Candida B V Fragoso; Gary D Hammer
Journal:  Clin Cancer Res       Date:  2019-02-15       Impact factor: 12.531

4.  Nicotine induced CpG methylation of Pax6 binding motif in StAR promoter reduces the gene expression and cortisol production.

Authors:  Tingting Wang; Man Chen; Lian Liu; Huaiyan Cheng; You-E Yan; Ying-Hong Feng; Hui Wang
Journal:  Toxicol Appl Pharmacol       Date:  2011-09-24       Impact factor: 4.219

5.  Seladin-1 expression is regulated by promoter methylation in adrenal cancer.

Authors:  Lisa Simi; Francesca Malentacchi; Paola Luciani; Stefania Gelmini; Cristiana Deledda; Rosaria Arvia; Massimo Mannelli; Alessandro Peri; Claudio Orlando
Journal:  BMC Cancer       Date:  2010-05-13       Impact factor: 4.430

Review 6.  Fetal programming of adrenal androgen excess: lessons from a nonhuman primate model of polycystic ovary syndrome.

Authors:  David H Abbott; Rao Zhou; Ian M Bird; Daniel A Dumesic; Alan J Conley
Journal:  Endocr Dev       Date:  2008

Review 7.  The 'omics' of adrenocortical tumours for personalized medicine.

Authors:  Guillaume Assié; Anne Jouinot; Jérôme Bertherat
Journal:  Nat Rev Endocrinol       Date:  2014-02-04       Impact factor: 43.330

Review 8.  The role of 21-hydroxylase in the pathogenesis of adrenal masses: review of the literature and focus on our own experience.

Authors:  L Barzon; P Maffei; N Sonino; C Pilon; L Baldazzi; A Balsamo; O Del Maschio; G Masi; M Trevisan; M Pacenti; F Fallo
Journal:  J Endocrinol Invest       Date:  2007 Jul-Aug       Impact factor: 4.256

9.  Inhibin alpha-subunit (INHA) expression in adrenocortical cancer is linked to genetic and epigenetic INHA promoter variation.

Authors:  Johannes Hofland; Jacobie Steenbergen; Jacoba M Voorsluijs; Michael M P J Verbiest; Ronald R de Krijger; Leo J Hofland; Wouter W de Herder; Andre G Uitterlinden; Richard A Feelders; Frank H de Jong
Journal:  PLoS One       Date:  2014-08-11       Impact factor: 3.240

10.  Upregulation of CYP17A1 by Sp1-mediated DNA demethylation confers temozolomide resistance through DHEA-mediated protection in glioma.

Authors:  J-Y Chuang; W-L Lo; C-Y Ko; S-Y Chou; R-M Chen; K-Y Chang; J-J Hung; W-C Su; W-C Chang; T-I Hsu
Journal:  Oncogenesis       Date:  2017-05-22       Impact factor: 7.485

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.